致癌枢纽CIP2A的临床研究进展
Clinical Research Progress of Cancer Axis CIP2A
摘要: 靶向酪氨酸和丝氨酸苏氨酸激酶作为癌症的潜在治疗方式近期引起了极大关注，但是仅依靠激酶抑制是不够的，应将激酶抑制与激活肿瘤抑制磷酸酶比如蛋白酶磷酸酶2A (PP2A)结合应用于癌症治疗。蛋白磷酸酶2A癌性抑制因子(cancerous inhibitor of protein phosphatase 2A, CIP2A)是蛋白磷酸酶2A (protein phosphatase 2A, PP2A)的内源性抑制剂，它主要通过抑制PP2A使Akt去磷酸化并稳定癌蛋白MYC发挥致癌作用，多项研究表明CIP2A在多种肿瘤中高表达，是肿瘤诊断、预后的潜在生物学标志物，并参与多种肿瘤耐药性的形成，将CIP2A作为细胞毒药物作用的潜在靶标的研究日益增多。因此本文对CIP2A的生物学功能，CIP2A在恶性肿瘤中研究现状作一综述，旨在为癌症患者的临床治疗提供参考依据。
Abstract: Recently targeted tyrosine and serine threonine kinases have attracted much attention as potential treatments for cancer, but kinase inhibition alone is not enough and should be applied to cancer therapy in combination with the activation of tumor suppressor phosphatases such as protease phosphatase 2A (PP2A). Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an endogenous inhibitor of PP2A, which plays an carcinogenic role by mainly inhibiting PP2A to dephosphorylate Akt and stabilize carcinomatous protein MYC. Many studies have shown that CIP2A is highly expressed in a variety of tumors, and it is a potential biological marker for tumor diagnosis and prognosis, and participates in the formation of a variety of tumor drug resistance. More and more studies have focused on CIP2A as a potential target for the action of cytotoxic drugs. Therefore, in this paper, the biological function of CIP2A and the research status of CIP2A in malignant tumor were reviewed, aiming to provide reference basis for clinical treatment of cancer patients.
文章引用：李琳裕, 王丰梅. 致癌枢纽CIP2A的临床研究进展[J]. 临床医学进展, 2021, 11(9): 3995-4000. https://doi.org/10.12677/ACM.2021.119583

参考文献

[1] Chen, W., Liang, J.L., Zhou, K., Zeng, Q.L., Ye, J.W. and Huang, M.J. (2020) Effect of CIP2A and Its Mechanism of Action in the Malignant Biological Behavior of Colorectal Cancer. Cell Communication and Signaling, 18, 67. [Google Scholar] [CrossRef] [PubMed]
[2] Ma, L., Wen, Z.S., Liu, Z., Hu, Z. and Zhou, G.B. (2011) Overexpression and Small Molecule-Triggered Downregulation of CIP2A in Lung Cancer. PLoS ONE, 6, e20159. [Google Scholar] [CrossRef] [PubMed]
[3] Wang, J., Okkeri, J., Pavic, K., Wang, Z., Kauko, O., Halonen, T., Sarek, G., Ojala, P.M., Rao, Z., Xu, W. and Westermarck, J. (2017) Oncoprotein CIP2A Is Stabilized via Interaction with Tumor Suppressor PP2A/B56. EMBO Reports, 18, 437-450. [Google Scholar] [CrossRef] [PubMed]
[4] Denk, S., Schmidt, S., Schurr, Y., Schwarz, G., Schote, F., Diefenbacher, M., Armendariz, C., Dejure, F., Eilers, M. and Wiegering, A. (2020) CIP2A Regulates MYC Translation (via Its 5’UTR) in Colorectal Cancer. International Journal of Colorectal Disease, 36, 911-918. [Google Scholar] [CrossRef] [PubMed]
[5] Austin, J.A., Jenkins, R.E., Austin, G.M., Glenn, M.A. and Clark, R.E. (2019) Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) Modifies Energy Metabolism via 5’AMP-Activated Protein Kinase Signalling in Malignant Cells. Biochemical Journal, 476, BCJ20190121. [Google Scholar] [CrossRef] 
[6] Khan, M.M., Ullah, U., Khan, M.H., Kong, L., Moulder, R., Valikangas, T., Bhosale, S.D., Komsi, E., Rasool, O., Chen, Z., Elo, L.L., Westermarck, J. and Lahesmaa, R. (2020) CIP2A Constrains Th17 Differentiation by Modulating STAT3 Signaling. iScience, 23, Article ID: 100947. [Google Scholar] [CrossRef] [PubMed]
[7] Tian, Y., Chen, H., Qiao, L., Zhang, W., Zheng, J., Zhao, W., Chen, J.J. and Zhang, W. (2018) CIP2A Facilitates the G1/S Cell Cycle Transition via B-Myb in Human Papillomavirus 16 Oncoprotein E6-Expressing Cells. Journal of Cellular and Molecular Medicine, 22, 4150-4160. [Google Scholar] [CrossRef] [PubMed]
[8] Clark, R.E., Basabrain, A.A., Austin, G.M., Holcroft, A.K., Loaiza, S., Apperley, J.F., Law, C., Scott, L., Parry, A.D., Bonnett, L. and Lucas, C.M. (2021) Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia. Cancers (Basel), 13, 2155. [Google Scholar] [CrossRef] [PubMed]
[9] Makela, E., Pavic, K., Varila, T., Salmenniemi, U., Loyttyniemi, E., Nagelli, S.G., Ammunet, T., Kahari, V.M., Clark, R.E., Elo, L.L., Bachanaboyina, V.K., Lucas, C.M., Itala-Remes, M. and Westermarck, J. (2021) Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias. Clinical Cancer Research, 27, 2848-2860. [Google Scholar] [CrossRef] 
[10] Aslan, F., Guney, G., Avcikurt, A.S., Taskin, M.I. and Akgun, G.A. (2020) Relationship between CIP2A and Endometrium Cancer. Journal of College of Physicians and Surgeons Pakistan, 30, 373-378. [Google Scholar] [CrossRef] [PubMed]
[11] Guo, B., Wu, S., Zhu, X., Zhang, L., Deng, J., Li, F., Wang, Y., Zhang, S., Wu, R., Lu, J. and Zhou, Y. (2020) Micropeptide CIP2A-BP Encoded by LINC00665 Inhibits Triple-Negative Breast Cancer Progression. EMBO Journal, 39, e102190. [Google Scholar] [CrossRef] [PubMed]
[12] 刘喜婷, 杨磊, 马琴, 顾峰, 吴玉强. Wnt信号通路介导CIP2A沉默诱导肺癌细胞凋亡[J]. 中国老年学杂志, 2019, 39(12): 2982-2986.
[13] Saafan, H., Alahdab, A., Michelet, R., Gohlke, L. and Ritter, C.A. (2021) Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line. Cells, 10, 716. [Google Scholar] [CrossRef] [PubMed]
[14] Nishio, E., Hayashi, T., Akaza, M., Hisatomi, Y., Hikichi, M., Fujii, T., Utsumi, T., Harada, N. and Shimono, Y. (2020) Upregulation of CIP2A in Estrogen Depletion-Resistant Breast Cancer Cells Treated with Low-Dose Everolimus. FEBS Open Bio, 10, 2072-2080. [Google Scholar] [CrossRef] [PubMed]
[15] Zhu, Z. and Wei, Z. (2021) CIP2A Silencing Alleviates Doxorubicin Resistance in MCF7/ADR Cells through Activating PP2A and Autophagy. Clinical and Translational Oncology, 23, 1542-1548. [Google Scholar] [CrossRef] [PubMed]
[16] Kim, S.H., Lee, W.H., Seong, D., An, J.H., Je, H.U., Nam, H.Y., Kim, S.Y., Kim, S.W. and Han, M.W. (2019) The Role of CIP2A as a Therapeutic Target of Rapamycin in Radioresistant Head and Neck Cancer with TP53 Mutation. Head Neck, 41, 3362-3371. [Google Scholar] [CrossRef] [PubMed]
[17] Feng, F., Cheng, P., Wang, C., Wang, Y. and Wang, W. (2019) Polyphyllin I and VII Potentiate the Chemosensitivity of A549/DDP Cells to Cisplatin by Enhancing Apoptosis, Reversing EMT and Suppressing the CIP2A/AKT/mTOR Signaling Axis. Oncology Letters, 18, 5428-5436. [Google Scholar] [CrossRef] [PubMed]
[18] Shen, F., Chen, Y., Chen, L., Qin, J. and Xu, J. (2019) Amentoflavone Promotes Apoptosis in Non-Small-Cell Lung Cancer by Modulating Cancerous Inhibitor of PP2A. The Anatomical Record Advances in Integrative Anatomy and Evolutionary Biology, 302, 2201-2210. [Google Scholar] [CrossRef] [PubMed]
[19] Feng, F.-F., Cheng, P., Sun, C., Wang, H. and Wang, W. (2019) Inhibitory Effects of Polyphyllins I and VII on Human Cisplatin-Resistant NSCLC via p53 Upregulation and CIP2A/AKT/mTOR Signaling Axis Inhibition. Chinese Journal of Natural Medicines, 17, 768-777. [Google Scholar] [CrossRef] 
[20] 张洪兰, 陈昊, 张春芳, 张昶, 齐冬雪, 李伟, 刘新丽, 刘华. 贲门胃底癌中CIP2A mRNA表达与HER-2基因的扩增及其意义[J]. 实用医学杂志, 2018, 34(24): 4032-4036.
[21] Lin, X., Gao, M., Zhang, A., Tong, J., Zhang, X., Su, Q., Yang, Z., Gao, H. and Jiang, G. (2019) FL118 Inhibits Viability and Induces Apoptosis of Colorectal Cancer Cells via Inactivating the CIP2A/PP2A Axis. Life Sciences, 239, Article ID: 117074. [Google Scholar] [CrossRef] [PubMed]
[22] 杨雪, 张靖, 韩少山, 陶杰, 孙昊, 刘青光. 抑制CIP2A表达对肝癌细胞HepG2生物学特性影响的体内外研究[J]. 西安交通大学学报(医学版), 2019, 40(3): 362-367.
[23] 庞荣, 周全, 李茂. 异丙酚通过调节CIP2A-PP2A通路抑制HepG2细胞增殖[J]. 宁夏医科大学学报, 2020, 42(12): 1207-1211.
[24] Zhang, S. and Wang, K. (2020) miR-383 Down-Regulates the Oncogene CIP2A to Influence Glioma Proliferation and Invasion. OncoTargets and Therapy, 13, 4063-4074. [Google Scholar] [CrossRef] 
[25] Liu, C.Y., Huang, T.T., Chen, Y.T., Chen, J.L., Chu, P.Y., Huang, C.T., Wang, W.L., Lau, K.Y., Dai, M.S., Shiau, C.W. and Tseng, L.M. (2019) Targeting SET to Restore PP2A Activity Disrupts an Oncogenic CIP2A-Feedforward Loop and Impairs Triple Negative Breast Cancer Progression. EBioMedicine, 40, 263-275. [Google Scholar] [CrossRef] [PubMed]
[26] Gao, D., Nyalali, A.M.K., Hou, Y., Xu, Y., Zhou, J., Zhao, W., Huang, B. and Li, F. (2021) 2,5-Dimethyl Celecoxib Inhibits Proliferation and Cell Cycle and Induces Apoptosis in Glioblastoma by Suppressing CIP2A/PP2A/Akt Signaling Axis. Journal of Molecular Neuroscience, 71, 1703-1713. [Google Scholar] [CrossRef] [PubMed]
[27] Gao, H., Li, Y., Lin, T., Cheng, Y. and Ma, Y. (2020) Downregulation of CIP2A Inhibits Cancer Cell Proliferation and Vascularization in Renal Clear Cell Carcinoma. Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 164, 196-202. [Google Scholar] [CrossRef] [PubMed]
[28] Zhang, Y., Fang, L., Zang, Y., Ren, J. and Xu, Z. (2018) CIP2A Promotes Proliferation, Invasion and Chemoresistance to Cisplatin in Renal Cell Carcinoma. Journal of Cancer, 9, 4029-4038. [Google Scholar] [CrossRef] [PubMed]
[29] Ma, W., Xiang, Y., Yang, R., Zhang, T., Xu, J., Wu, Y., Liu, X., Xiang, K., Zhao, H., Liu, Y. and Si, Y. (2019) Cucurbitacin B Induces Inhibitory Effects via the CIP2A/PP2A/C-KIT Signaling Axis in t(8;21) Acute Myeloid Leukemia. Journal of Pharmacological Sciences, 139, 304-310. [Google Scholar] [CrossRef] [PubMed]

为你推荐